Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/13768| Title: | Temozolomide-associated liver fibrosis | Austin Authors: | Parakh, Sagun ;Hamid, Anis A;Cher, Lawrence M ;Gan, Hui K | Affiliation: | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia |
Issue Date: | Nov-2016 | Date: | 2016-04-20 | Publication information: | The Journal of Clinical Pharmacology 2016; 56(11): 1448-1449 | Abstract: | Temozolomide is generally well tolerated and severe hepatic toxicities associated with temozolomide are rare. We report a case of liver fibrosis in a patient on temozolomide for the treatment of GBM. This article is protected by copyright. All rights reserved. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/13768 | DOI: | 10.1002/jcph.753 | ORCID: | 0000-0002-7193-9723 | Journal: | The Journal of Clinical Pharmacology | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/27094014 | Type: | Journal Article | Subjects: | Temozolomide Liver Cirrhosis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.